Слайд 2 Rubella, commonly known as German measles, is
a disease caused by Rubella virus. The name is derived
from the Latin language, meaning little red. Rubella is also known as German measles because the disease was first described by German physicians in the mid-eighteenth century. This disease is often mild and attacks often pass unnoticed. The disease can last one to five days. Children recover more quickly than adults. Infection of the mother by Rubella virus during pregnancy can be serious; if the mother is infected within the first 20 weeks of pregnancy, the child may be born with congenital rubella syndrome (CRS), which entails a range of serious incurable illnesses. Spontaneous abortion occurs in up to 20% of cases. Rubella is a common childhood infection usually with minimal systemic upset although transient arthropathy may occur in adults. Serious complications are very rare. If it were not for the effects of transplacental infection on the developing foetus, rubella is a relatively trivial infection. In most people the virus is rapidly eliminated. However, it may persist for some months post partum in infants surviving the CRS. These children were an important source of infection to other infants and, more importantly, pregnant female contacts.
Слайд 3tHiS dIsEaSe iS cAuSeD bY….
RUBELLA VIRUS
FAMILY: TOGAVIRIDAE
GENUS: RUBIVIRUS
Слайд 4MORPHOLOGY
Rubella virus is a spherical, 40 to 80 nm, positive-sense,
single-stranded RNA virus with spike-like, haemagglutinin-containing surface projections. An electron-dense
30 to 35 nm core is surrounded by a lipoprotein envelope.
The virus particle, or virion, is enveloped and approximately 60nm in diameter. The virion consists of a single polyadenylated molecule of RNA enclosed in a nucleocapsid.
The surounding envelope is derived from the host cell membrane and viral glycoproteins that form projections approximately 6nm long.
The viral RNA has two open reading frames (ORFs) and untranslated regions (UTRs) at the 5' and 3' ends of the genome.
The virus contains three glycosylated, membrane- associated proteins, El, E2a and E2b, and one unglycosylated nucleocapsid protein, C .
Слайд 6REPLICATION
Rubella virus replicates in the cytoplasm of host cells.
The viral genomic RNA serves as a template for
the synthesis of negative sense RNAs which are used to produce cytoplasmic messenger RNA (mRNA).
The mRNAs direct the production of viral proteins and are also packaged as genomic RNA in virions.
The steps are similar to other togoviruses but with the expection that nucleocapsids do not accumulate in the cytoplasm,
Continuous carrier cultures are not uncommon and frequently show many chromosomal breaks and abnormalities,
Слайд 7EPIDEMIOLOGY
Rubella is a disease that occurs worldwide.
The virus tends to peak during the spring in countries
with temperate climates. Before the vaccine to rubella was introduced in 1969, widespread outbreaks usually occurred every 6-9 years in the United States and 3-5 years in Europe, mostly affecting children in the 5-9 year old age group. Since the introduction of vaccine, occurrences have become rare in those countries with high uptake rates. However, in the UK there remains a large population of men susceptible to rubella who have not been vaccinated. Outbreaks of rubella occurred amongst many young men in the UK in 1993 and in 1996 the infection was transmitted to pregnant women, many of whom were immigrants and were susceptible. Outbreaks still arise, usually in developing countries where the vaccine is not as accessible.
During the epidemic in the US between 1962-1965, Rubella virus infections during pregnancy were estimated to have caused 30,000 still births and 20,000 children to be born impaired or disabled as a result of CRS. Universal immunisation producing a high level of herd immunity is important in the control of epidemics of rubella.
Слайд 9PATHOGENESIS & CLINICAL
SYNDROMES
Rubella is highly contagious disease spread
by nasal secretions. Because infection often is inapparent, viral dissemination maybe widespread before it is recognized.
Rubella virus infects the upper respiratory tract & then spread to local lymph nodes, which coincides with a period of lymphadenopathy. This is followed by establishment of viremia, which spreads the virus throughout the body. Infection of other tissues and the characteristic mild rash result. The prodromal period lasts approximately 2 weeks. The person can shed virus in respiratory droplet during the prodromall period and for as long as 2 weeks after the onset of the rash.
Слайд 10SIGNS & SYMPTOMS
After an incubation period of 14-21 days, the
primary symptom of rubella virus infection is the appearance of
a rash (exanthem) on the face which spreads to the trunk and limbs and usually fades after three days. Other symptoms include low grade fever, swollen glands (post cervical lymphadenopathy), joint pains, headache, conjunctivitis. The swollen glands or lymph nodes can persist for up to a week and the fever rarely rises above 38°C (100.4°F). The rash disappears after a few days with no staining or peeling of the skin. Forchheimer's sign occurs in 20% of cases, and is characterized by small, red papules on the area of the soft palates.
Rubella can affect anyone of any age and is generally a mild disease, rare in infants or those over the age of 40. The older the person is the more severe the symptoms are likely to be. Up to one-third of older girls or women experience joint pain or arthritic type symptoms with rubella. The virus is contracted through the respiratory tract and has an incubation period of 2 to 3 weeks. During this incubation period, the carrier is contagious but may show no symptoms.
Слайд 11IMMUNITY
Antibody is generated after the viremia, and its appearance correlates
with the appearance of the rash. The antibody limits viremic
spread, but cell mediated immunity plays an important role in resolving the infection. Natural infection produces lifelong protective immunity. Serum antibody in pregnant woman prevents spread of the virus to the fetus.
Слайд 12CONGENITAL RUBELLA SYNDROME (CRS)
Rubella can cause congenital rubella syndrome in
the newly born. The syndrome (CRS) follows intrauterine infection by
Rubella virus and comprises cardiac, cerebral, ophthalmic and auditory defects. It may also cause prematurity, low birth weight, and neonatal thrombocytopenia, anaemia and hepatitis. The risk of major defects or organogenesis is highest for infection in the first trimester. CRS is the main reason a vaccine for rubella was developed. Many mothers who contract rubella within the first critical trimester either have a miscarriage or a still born baby. If the baby survives the infection, it can be born with severe heart disorders (PDA being the most common), blindness, deafness, or other life threatening organ disorders. The skin manifestations are called "blueberry muffin lesions."
Слайд 13 CRS can result in serious birth defects such as:
malformations of
the heart (especially patent ductus arteriosus), eyes or brain
deafness
spleen, liver or bone marrow problems (some of which may disappear shortly after birth)
Mental retardation
small head size (microcephaly)
eye defects (especially cataract and microphthalmia
low birth weight
thrombocytopenic purpura (presents as a characteristic "blueberry muffin" rash)
hepatomegaly
micrognathia
Children who have been exposed to rubella in the womb should also be watched closely as they age for any indication of the following:
Develpomental delay
schizophrenia
Growth retardation
Learning disabilities
Diabetes
glaucoma
Слайд 14LABORATORY DIAGNOSIS
Serological method – used for detection of anti-rubella-specific IgM.
A
fourfold increase on specific IgG antibody titer between acute &
convalescent sera is also used to indicate a recent infection.
Antibodies to rubella are assayed early in pregnancy to determine the immune status of the woman.
Virological method is used rarely.
Virus is obtained from urine and is detected by the interference with ECHO 11 virus replication in primary African green monkey kidney cell cultures.
Слайд 15PREVENTION
Rubella infections are prevented by active immunisation programs using live,
disabled virus vaccines. Two live attenuated virus vaccines, RA 27/3
and Cendehill strains, were effective in the prevention of adult disease. However their use in prepubertile females did not produce a significant fall in the overall incidence rate of CRS in the UK. Reductions were only achieved by immunisation of all children.
The vaccine is now given as part of the MMR vaccine. The WHO recommends the first dose is given at 12 to 18 months of age with a second dose at 36 months. Pregnant women are usually tested for immunity to rubella early on. Women found to be susceptible are not vaccinated until after the baby is born because the vaccine contains live virus.
The immunization program has been quite successful with Cuba declaring the disease eliminated in the 1990s. In 2004 the Centres for Disease Control & Prevention announced that both the congenital and acquired forms of rubella had been eliminated from the United States.
Слайд 16TREATMENT & PROPHYLAXIS
Symptoms are usually treated with paracetamol until the
disease has run its course. Treatment of newly born babies
is focused on management of the complications. Congenital heart defects and cataracts can be corrected by surgery. Management for ocular CRS is similar to that for age-related macular degeneration, including counseling, regular monitoring, and the provision of low vision devices, if required.
The life rubella vaccine is usually administered with the measles and mumps vaccines (MMR vaccine). The triple vaccine is included routinely in well-baby care. Vaccination promotes both humoral and cellular immunity.